Over 450 Total Lots Up For Auction at Three Locations - CO 05/12, PA 05/15, NY 05/20

Harrie Buurlage

Shine Medical Technologies appoints vice president of European operations
September 06, 2019
Molecular Imaging
Harrie Buurlage
JANESVILLE, Wis., Sept. 4, 2019 – SHINE Medical Technologies LLC today announced the appointment of Harrie Buurlage as vice president, European operations. Mr. Buurlage will oversee all of SHINE's activities in Europe, including the company's siting, construction and operation of a medical isotope production facility there.

Mr. Buurlage brings more than 25 years of experience in the nuclear medicine industry to his new role at SHINE, including positions in management, operations, and sales and marketing.

Mr. Buurlage was chief operating officer and then managing director of NRG, an international nuclear service provider, in the Netherlands. Among other things, Mr. Buurlage oversaw the operation of all of NRG's nuclear installations, including the Dutch High Flux medical isotope production facility in Petten, which produces isotopes used in more than 30,000 patient treatments a day. He led a multi-year transition of the company from a science institute to a more robust health care organization.
stats
DOTmed text ad

Your Trusted Source for Sony Medical Displays, Printers & More!

Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.

stats
Before joining NRG, Mr. Buurlage was global director of manufacturing for Covidien USA, now Curium Pharma, where he was responsible for radiopharmaceutical isotope manufacturing and distribution at facilities in the Netherlands, United Kingdom and United States. Mr. Buurlage oversaw the addition of a new reactor to Covidien's supply chain in only nine months. He also drove logistical improvements in Europe, the Middle East and Africa, and was global chairman of the company's nuclear medicine council.

Earlier in this career, Mr. Buurlage spent nearly 15 years at Mallinckrodt, where he served in positions of increasing responsibility at Petten, including managing director of Mallinckrodt Medical (MM) B.V. and director of EMEA operations.

"It is well known that current European producers of medical isotopes are planning to cease operations in the next several years, and SHINE is excited to be in a position to ensure that Europeans have uninterrupted access to the life-saving products our team and technology can provide," said Greg Piefer, founder and CEO of SHINE. "Harrie's experience in the nuclear industry and European market, and his management, operations and logistics expertise will be invaluable to SHINE as we execute our plan there. We look forward to working with Harrie to make a SHINE European presence a reality, and provide for a robust European and global supply chain."

Mr. Buurlage studied applied physics at the University of Groningen. He earned certification as a radiation safety officer at the University of Leiden, the highest-level certification of its kind in Europe, which allows holders to supervise large, complex nuclear sites.

You Must Be Logged In To Post A Comment

 

advertisement

Molecular Imaging Homepage

SHINE Technologies to acquire Lantheus’ SPECT division
Deal includes the manufacturing operations at Lantheus’ North Billerica, Massachusetts site
Blue Earth Therapeutics begins phase 2 trial of lutetium-based radioligand for prostate cancer
Assessing efficacy and safety across different dosing regimens
SpectronRx passes FDA inspection with no observations for Indianapolis facility
Plans to expand operations to meet global demand for radiopharmaceuticals
SHINE enters UAE market with Modawina partnership for Lu-177 distribution
Extends presence across the Europe, Middle East, and Africa regions
PET procedure volumes in US rose 12% in 2024
Demand grew alongside limited expansion in installed imaging capacity, according to IMV
SHINE and Sumitomo form partnership to expand radioisotope supply in Asia
The agreement will focus on establishing supply chains for SHINE’s core offerings
FDA clears Novartis’ Pluvicto for earlier use in PSMA-positive prostate cancer
Approved for patients who received one androgen receptor pathway inhibitor (ARPI) but not chemotherapy
GE HealthCare takes full ownership of Nihon Medi-Physics in Japan
Bolsters footprint in PET and SPECT radiopharmaceuticals
World Theranostics Day: The dawn of precision cancer care
Insights from Dr. Ilya Gipp, oncology chief medical officer at GE HealthCare
GE HealthCare and Swiss Medical Network launch molecular imaging center focused on theranostics
Will utilize Omni Legend 32 PET/CT, StarGuide SPECT/CT, and 870DR systems